3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 1/2
2
Phase 2
1
Status
Terminated
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Melanoma
101
Carcinoma, Non-Small-Cell Lung
88
Carcinoma, Renal Cell
54
Neoplasm Metastasis
37
Squamous Cell Carcinoma of Head and Neck
32
Colorectal Neoplasms
32
Carcinoma, Hepatocellular
32
Lung Neoplasms
31
Hodgkin Disease
25
Neoplasms
24
Urinary Bladder Neoplasms
21
Pancreatic Neoplasms
21
Carcinoma, Transitional Cell
20
Breast Neoplasms
19
Stomach Neoplasms
17
Brain Neoplasms
17
Prostatic Neoplasms
16
Small Cell Lung Carcinoma
15
Sarcoma
15
Multiple Myeloma
14
Head and Neck Neoplasms
14
Esophageal Neoplasms
14
Glioblastoma
11
Uterine Cervical Neoplasms
10
Rectal Neoplasms
10
Neuroendocrine Tumors
10
Lymphoma
10
Recurrence
9
Ovarian Neoplasms
9
Nasopharyngeal Carcinoma
9
Interventions
Paclitaxel
2
Injections
2
toripalimab
1
tislelizumab
1
surufatinib
1
sotorasib
1
osimertinib
1
netrin-1 inhibitor NP137
1
lazertinib
1
fluzoparib
1
camrelizumab
1
Panitumumab
1
PM 01183
1
Nivolumab
1
Ipilimumab
1
HMPL-013
1
Erlotinib Hydrochloride
1
Dexamethasone
1
Calcium Dobesilate
1
Bortezomib
1
Bevacizumab
1
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Solid Tumors
×
Nivolumab
×
Clear all
NCT03461952
2024-02-22
NIMBLe
Canadian Cancer Trials Group
Phase 2
Terminated
4 enrolled
4 charts